Purple Biotech Ltd PPBT.OQ, PPBT.O is expected to show no change in quarterly revenue when it reports results on March 3 (estimated) for the period ending June 30 2024
LSEG's mean analyst estimate for Purple Biotech Ltd is for a loss of $1.80 per share.
The one available analyst rating on the shares is "buy".
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Purple Biotech Ltd is $33.00, above its last closing price of $2.85.
This summary was machine generated February 28 at 13:33 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。